Suppr超能文献

原发性甲状腺功能减退症患者服用左甲状腺素后氧化应激。

Oxidative stress following administration of levothyroxine in subjects suffering from primary hypothyroidism.

机构信息

Loyola University School of Medicine, Chicago, IL, USA.

出版信息

Panminerva Med. 2011 Sep;53(3 Suppl 1):95-8.

Abstract

AIM

Oxidative stress (OS) in subjects with primary hypothyroidism under therapy with L-T4 might be the cause of the side effects commonly found with this treatment.

METHODS

Twenty-four subjects of both sexes (11 M and 15 F), aged between 41 and 61 years, with primary hypothyroidism were assessed. All the subjects were followed for 30 days during the administration of a fixed dose of 75 μg of L-T4. Levels of T4, T3, TSH, hydroperoxides (as measure of OS ), hs-CRP were determined in plasma before and after the treatment. Side effects (anxiety/agitation, sweating, palpitations and headache) and number of days of discomfort were measured for 15 days before and for two subsequent 15-day periods.

RESULTS

Administration of L-T4 satisfactorily balanced the hypothyroidism. A high level of hydroperoxides, 370 ± 27.7 U.CARR. (Carratelli Units: 1 U.CARR. = 0.08 mg of H2O2/L), was observed before treatment, and L-T4 administration further increased the level up to 435 ± 39.5 U.CARR (p<0.05). The treatment produces a significant increase in hs-CRP, from 3.2 ± 2.32 to 4.0 ± 1.27 mg/L (P<0.05). Side effects, almost absent at the baseline 15-day control, occurred with high frequencies during the treatment: between 9.6 ± 1.14 days/15 days for sweating and 14.1 ± 0.93 days/15 days for palpitations. Some side effects were found to be linearly correlated with hydroperoxides (r=0.641, P<0.01 and r=0.658, P<0.01 respectively) or with hs-CRP, as in the case of anxiety/agitation (r=0.629, P<0.01). Following L-T4 administration the days of discomfort turned out to be particularly prominent during the two subsequent 15-day controls (3.8 ± 0.75 and 4.8 ± 0.78 days respectively).

CONCLUSION

Primary hypothyroidism and therapy with L-T4 at a dose of 75 μg/day cause OS. Side effects following L-T4 therapy depend on OS and cause daily discomfort and loss of working activity in about 1/3 of the days considered.

摘要

目的

在接受 L-T4 治疗的原发性甲状腺功能减退症患者中,氧化应激(OS)可能是这种治疗常见副作用的原因。

方法

评估了 24 名年龄在 41 至 61 岁之间的原发性甲状腺功能减退症的男女患者(11 名男性和 15 名女性)。所有患者在接受固定剂量 75μg L-T4 的治疗期间,均随访 30 天。在治疗前后测定血浆中 T4、T3、TSH、过氧化物(OS 的衡量标准)、hs-CRP 的水平。在治疗前的 15 天和随后的两个 15 天期间,测量了 15 天的副作用(焦虑/激动、出汗、心悸和头痛)和不适天数。

结果

L-T4 的给药使甲状腺功能减退症得到了满意的平衡。治疗前观察到高水平的过氧化物,为 370±27.7 U.CARR(Carratelli 单位:1 U.CARR = 0.08mg H2O2/L),而 L-T4 的给药使水平进一步增加至 435±39.5 U.CARR(p<0.05)。治疗后 hs-CRP 显著升高,从 3.2±2.32mg/L 升高至 4.0±1.27mg/L(P<0.05)。副作用,在基线 15 天对照时几乎不存在,但在治疗期间出现的频率很高:出汗的频率为 9.6±1.14 天/15 天,心悸的频率为 14.1±0.93 天/15 天。一些副作用与过氧化物(r=0.641,P<0.01 和 r=0.658,P<0.01)或 hs-CRP 呈线性相关,如焦虑/激动(r=0.629,P<0.01)。在 L-T4 给药后,在随后的两个 15 天对照期间,不适天数明显突出(分别为 3.8±0.75 和 4.8±0.78 天)。

结论

原发性甲状腺功能减退症和 75μg/天的 L-T4 治疗会引起 OS。L-T4 治疗后的副作用取决于 OS,并导致大约 1/3 的日子出现日常不适和丧失工作活动能力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验